<DOC>
	<DOCNO>NCT00532077</DOCNO>
	<brief_summary>SB-751689 may alter calcium phosphate handle kidney level . This study examine happen calcium phosphate , electrolytes , kidney treatment SB-751689 1 month . Another group subject get another drug call Forteo 1 month compare response kidney calcium phosphate .</brief_summary>
	<brief_title>A Study Evaluate Effects SB-751689 rhPTH ( 1-34 ) Excretion Calcium Phosphate Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Healthy postmenopausal woman 40 65 year age , inclusive , meet least one following : Postmenopausal define STRAW criterion 12 month spontaneous amenorrhea serum FSH level = 40 mIU/mL ; History bilateral oophorectomy ( without hysterectomy ) least 6 week postsurgical serum FSH level = 40 mIU/mL Body weight &gt; 50 kg BMI within range 19 32 kg/m2 Capable give write informed consent Any clinically relevant biological physical abnormality find report screening , opinion investigator , clinically significant would preclude safe participation study . These abnormality may identify screen history physical laboratory examination 12lead electrocardiogram ( ECG ) . A subject may participate study follow laboratory result upper limit normal range screening : liver function test ( ALT , AST , GGT , alkaline phosphatase , total bilirubin ) , plasma amylase , glucose , alkaline phosphatase , CPK . A subject may participate study follow laboratory result outside normal range screening : serum level albuminadjusted calcium , total calcium , PTH , urinary calcium . A subject vitamin D deficiency define serum 25hydroxy vitamin D &lt; 20 ng/mL ( equivalent 50 nmol/L ) screening may participate study . A QTc interval &gt; 450 msec screening . Positive urine drug screen . Positive HIV , hepatitis B virus hepatitis C virus assay . Urinary cotinine level indicative smoking . History smoking use nicotine containing product within one year screening . History regular alcohol consumption History drug abuse within 6 month study . Participation study investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , calcium contain antacid , aspirin nonsteroidal antiinflammatory drug , vitamin , herbal dietary supplement , exclude study relate vitamin D calcium supplement , within 14 day prior first dose study medication . Donation blood excess 500 mL within 56 day prior dose . Evidence hepatic biliary disease ( include cholecystectomy Gilbert 's Syndrome ) . Significant renal disease define : Serum creatinine clearance &lt; 60ml/min ( estimate serum creatinine ( SCr ) demographic data use MDRD calculation ) : A validated webbased calculator find : http : //nephron.com/cgibin/MDRDSIdefault.cgi GFR Calculator To calculate estimate GFR ( mL/min/1.73m2 ) manually : = 186 x ( SCr mg/dL ) 1.154 x ( age ) 0.203 x ( 0.742 female ) x ( 1.210 AfricanAmerican ) = exp ( 5.2281.154 x ln ( SCr ) 0.203x ln ( age ) ( 0.299 female ) + ( 0.192 African American ) ) Urine protein/creatinine ( mg/mg ) ratio &gt; 2.5 ; urine albumin concentration &gt; 300 ug/mg . Known loss kidney , either surgically injury disease History significant gastrointestinal History gastrointestinal surgical procedure might affect absorption SB751689 History sensitivity study medication component thereof . History clinically significant cardiovascular disease . History pancreatitis kidney stone . Medical condition might alter bone metabolism Subjects increase risk osteosarcoma Paget 's disease bone prior external beam implant radiation therapy involve skeleton .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>renal ,</keyword>
	<keyword>pharmacology ,</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>